Xeris Pharmaceuticals, Inc. announced that Mr. Paul R. Edick has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective January 9, 2017. Mr. Edick is a highly accomplished pharmaceutical industry executive who most recently served as CEO of Durata Therapeutics, which he and his team built, took public, and sold to Actavis PLC, now known as Allergan PLC. He succeeds Mr. Douglas Baum, who is stepping down from his role as President and Chief Executive Officer and will serve as a consultant to the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.98 USD | -1.98% | +12.50% | -15.74% |
09/05 | Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.74% | 294M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+13.58% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Pharmaceuticals, Inc. Announces Executive Changes